Hoese & Co LLP Has $362,000 Stake in Johnson & Johnson (NYSE:JNJ)

Hoese & Co LLP increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 15.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,502 shares of the company’s stock after acquiring an additional 338 shares during the period. Johnson & Johnson accounts for about 0.3% of Hoese & Co LLP’s holdings, making the stock its 21st largest position. Hoese & Co LLP’s holdings in Johnson & Johnson were worth $362,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Summit Wealth Partners LLC raised its position in Johnson & Johnson by 0.6% in the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company’s stock valued at $1,463,000 after purchasing an additional 61 shares during the last quarter. Powers Advisory Group LLC increased its stake in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after buying an additional 61 shares during the period. Eagle Wealth Strategies LLC increased its stake in shares of Johnson & Johnson by 2.8% in the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock valued at $372,000 after buying an additional 63 shares during the period. Knuff & Co LLC increased its stake in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after buying an additional 64 shares during the period. Finally, Perkins Coie Trust Co increased its stake in shares of Johnson & Johnson by 1.8% in the 3rd quarter. Perkins Coie Trust Co now owns 3,705 shares of the company’s stock valued at $600,000 after buying an additional 65 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $145.39 on Thursday. The firm has a market cap of $350.04 billion, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 2.50 and a beta of 0.51. The stock’s 50-day moving average is $148.26 and its 200-day moving average is $156.12. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. During the same period in the previous year, the company posted $2.29 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 9.95 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.41%. Johnson & Johnson’s payout ratio is presently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Bank of America decreased their price objective on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a research note on Friday, January 17th. Citigroup decreased their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 17th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $173.27.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.